Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients

Psychiatry Research

Volumn 169, Issue 1, 2009, Pages 56-61

  Akanji, Abayomi O ^a   Ohaeri, Jude U ^b   Al Shammri, Suhail ^a   Fatania, Hasmukh R ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

^b Psychological Medicine Hospital Kuwait   (Kuwait)

Author keywords

Arabs; CRP; Cytokines; Disease phenotypes; Metabolic syndrome; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; C REACTIVE PROTEIN; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGED; ARAB; ARTICLE; BODY MASS; CATATONIA; CONTROLLED STUDY; DISEASE SEVERITY; ETHNIC GROUP; FAMILY HISTORY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; REMISSION; SCHIZOPHRENIA; SOCIAL STATUS;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOASSAY; KUWAIT; MALE; MIDDLE AGED; PHENOTYPE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 67651146330     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2008.06.010     Document Type: Article

References (40)

1. Akanji A.O., Al-Sulaiman A., Kinatamitath P., Safar F., Al-Zaid K., and Mojiminiyi O.A. Profile of hyperlipidaemic patients in Kuwait: frequency of cardiovascular disease risk factors at presentation and initial response to treatment. Journal of Kuwait Medical Association 29 (1997) 25-33
2. Al-Ansari E.A., Emara M.M., Mirza I.A., and el-Islam M.F. Schizophrenia in ICD-10: a field trial of suggested diagnostic guidelines. Comprehensive Psychiatry 30 (1989) 416-419
3. Albert C.M., Ma J., Rifai N., Stampfer M.J., and Ridker P.M. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 105 (2002) 2595-2599
4. Alberti K.G.M.M., Zimmet P., and Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 366 (2005) 1059-1062
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (1994), APA, Washington, DC
6. Andreasen, N.C., 1981. Scale for the Assessment of Negative Symptoms (SANS). University of Iowa, Iowa City, IA, USA.
7. Baptista T., Dávila A., El Fakih Y., Uzcátegui E., Rangel N.N., Olivares Y., Galeazzi T., Vargas D., Peña R., Marquina D., Villarroel V., Teneud L., and Beaulieu S. Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia. International Clinical Psychopharmacology 22 (2007) 205-211
8. Castell J.V., Gomez-Lechon M.J., David M., Fabra R., Trullenque R., and Heinrich P.C. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 12 (1990) 1179-1186
9. Dickerson F., Stallings C., Origoni A., Boronow J., and Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophrenia Research 93 (2007) 261-265
10. Dickerson F., Stallings C., Origoni A., Boronow J., and Yolken R. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Progress in Neuropsychopharmacology and Biological Psychiatry 31 (2007) 952-955
11. Douglas K.M., Taylor A.J., and O'Malley P.G. Relationship between depression and C-reactive protein in a screening population. Psychosomatic Medicine 66 (2004) 679-683
12. El-Hilu S.M., Mousa R., Abdulmalek H., Kamel N., Zohdi M., and al-Aamriti M. Psychiatric morbidity among foreign housemaids in Kuwait. International Journal of Social Psychiatry 36 (1990) 291-299
13. Fan X., Pristach C., Liu E.Y., Freudenreich O., Henderson D.C., and Goff D.C. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Research 149 (2007) 267-271
14. Guy W. The abnormal involuntary movement scale (AIMS). ECDEU Manual (1976), US Department of Health, Education & Welfare, Rockville, MD, USA 534-537
15. Handoko H.Y., Nancarrow D.J., Hayward N.K., Ohaeri J.U., Aghanwa H., McGrath J.J., Levinson D.F., Johns C., Walters M.K., Nertney D.A., Srinivasan T.N., Thara R., and Mowry B.J. Tumor necrosis factor haplotype analysis amongst schizophrenia probands from four distinct populations in the Asia-Pacific region. American Journal of Medical Genetics 121B (2003) 1-6
16. Hoffmann J.A., Kafatos F.C., Janeway C.A., and Ezekowitz R.A. Phylogenetic perspectives in innate immunity. Science 284 (1999) 1313-1318
17. Hoshi T., Kitagawa K., Yamagami H., Furukado S., Hougaku H., and Hori M. Relations of serum high-sensitivity C-reactive protein and interleukin-6 levels with silent brain infarction. Stroke 36 (2005) 768-772
18. Kay S.R., Fiszbein S., and Opler L.A. The Positive and Negative Syndrome Scale. Schizophrenia Bulletin 13 (1987) 331-355
19. Koenig W., Sund M., Frohlich M., Fischer H.G., Lowel H., Doring A., Hutchinson W.L., and Pepys M.B. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99 (1999) 237-242
20. Kop W.J., Gottdiener J.S., Tangen C.M., Fried L.P., McBurnie M.A., Walston J., Newman A., Hirsch C., and Tracy R.P. Inflammation and coagulation factors in persons > 65 years of age with symptoms of depression but without evidence of myocardial ischemia. American Journal of Cardiology 89 (2002) 419-424
21. Kudoh A., Sakai T., Ishihara H., and Matsuki A. Plasma cytokine response to surgical stress in schizophrenic patients. Clinical & Experimental Immunology 125 (2001) 89-93
22. Ledue T.B., and Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular risk assessment. Clinical Chemistry 49 (2003) 1258-1271
23. Lofstrom G. Comparison between the reaction of acute phase serum with pneumococcus C-polysaccharide and with pneumococcus type 27. British Journal of Experimental Pathology 25 (1944) 21-26
24. MacLeod C.M., and Avery O.T. The occurrence during acute infections of a protein not normally present in the blood. II. Isolation and properties of the reactive protein. Journal of Experimental Medicine 73 (1943) 183-191
25. Malasi T.H., Mirza I.A., and el-Islam M.F. Factors influencing long-term psychiatric hospitalisation of the elderly in Kuwait. International Journal of Social Psychiatry I35 (1989) 223-230
26. Mazzarello V., Cecchini A., Fenu G., Rassu M., Dessy L.A., Lorettu L., and Montella A. Lymphocytes in schizophrenic patients under therapy: serological, morphological and cell subset findings. Italian Journal of Anatomy and Embryology 109 (2004) 177-188
27. Miller G.E., Freedland K.E., Duntley S., and Carney R.M. Relation of depressive symptoms to C-reactive protein and pathogen burden (cytomegalovirus, herpes simplex virus, Epstein-Barr virus) in patients with earlier acute coronary syndromes. American Journal of Cardiology 95 (2005) 317-321
28. Naudin J., Mège J.L., Azorin J.M., and Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophrenia Research 20 (1996) 269-273
29. Ohaeri J.U., Hedo C.C., Enyidah N.S., and Ogunniyi A.O. Tissue injury-inducing potential of unmodified ECT: serial measurement of acute phase reactants. Convulsive Therapy 8 (1992) 253-257
30. Ohaeri J.U., Hedo C.C., and Lagundoye O.O. The profile of C-reactive protein in functional psychotic states in a Nigerian cohort. Acta Psychiatrica Scandinavica 88 (1993) 252-255
31. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New England Journal of Medicine 336 (1997) 973-979
32. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New England Journal of Medicine 342 (2000) 836-843
33. Ridker P.M., Stampfer M.J., and Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. Journal of the American Medical Association 285 (2001) 2481-2485
34. Rost N.S., Wolf P.A., Kase C.S., Kelly-Hayes M., Silbershatz H., Massaro J.M., D'Agostino R.B., Franzblau C., and Wilson P.W. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 32 (2001) 2575-2579
35. Shcherbakova I., Neshkova E., Dotsenko V., Platonova T., Shcherbakova E., and Yarovaya G. The possible role of plasma kallikrein-kinin system and leukocyte elastase in pathogenesis of schizophrenia. Immunopharmacology 43 (1999) 273-279
36. Soilu-Hanninen M., Koskinen J.O., Laaksonen M., Hanninen A., Lilius E.M., and Waris M. High sensitivity measurement of CRP and disease progression in multiple sclerosis. Neurology 65 (2005) 153-155
37. Tillet W.S., and Francis T. Serological reaction in pneumonia with a non-protein somatic fraction of pneumococcus. Journal of Experimental Medicine 52 (1930) 561-571
38. Wing J.K., Babor T., Brugha T., Burke J., Cooper J.E., Giel R., Jablenski A., Regier D., and Sartorius N. SCAN - schedules for clinical assessment in neuropsychiatry. Archives of General Psychiatry 47 (1990) 589-593
39. World Health Organization. International Statistical Classification of Diseases and Related Health Problems (1992), WHO, Geneva 10th Revision
40. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Cao L.Y., and Shen Y.C. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophrenia Research 57 (2002) 247-258